

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)**

Antimicrobial Drugs Advisory Committee (AMDAC) Meeting
FDA White Oak Campus, Building 31 Conference Center, Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
August 7, 2018

AGENDA

The committee will discuss new drug application (NDA) 207356, amikacin liposome inhalation suspension, sponsored by Inmed, Inc., for the proposed indication of treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium Complex (MAC) in adults as part of a combination antibacterial drug regimen.

8:30 a.m.	Call to Order and Introduction of Committee	Lindsey R. Baden, MD Chairperson, AMDAC
8:40 a.m.	Conflict of Interest Statement	Lauren D. Tesh, PharmD, BCPS Designated Federal Officer, AMDAC
8:45 a.m.	FDA Opening Remarks	Sumathi Nambiar MD, MPH Director Division of Anti-Infective Products (DAIP) Office of Antimicrobial Products (OAP) Office of New Drugs (OND), CDER, FDA
8:55 a.m.	APPLICANT PRESENTATIONS	Inmed, Inc.
	Introduction	Paul Streck, MD Chief Medical Officer Inmed, Inc.
	Unmet Need	Shannon Kasperbauer, MD Associate Professor Department of Medicine Division of Mycobacterial and Respiratory Infections National Jewish Health
	Efficacy	Eugene Sullivan, MD Chief Product Strategy Officer Inmed, Inc.
	Safety	Peter Sallstig, MD Vice President, Clinical Development Inmed, Inc.
	Clinical Perspective	David Griffith, MD Professor of Medicine University of Texas Health Science Center at Tyler
10:25 a.m.	Clarifying Questions	

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)**

Antimicrobial Drugs Advisory Committee (AMDAC) Meeting
August 7, 2018

AGENDA (cont.)

10:40 a.m. **BREAK**

10:50 a.m. **FDA PRESENTATIONS**

Presentation of Clinical Efficacy

Peter Kim, MD, MS
Clinical Team Leader
DAIP, OAP, OND, CDER, FDA

Presentation of Clinical Safety

Hiwot Hiruy, MD, PhD
Medical Officer
DAIP, OAP, OND, CDER, FDA

12:20 p.m. Clarifying Questions

12:35 p.m. **LUNCH**

1:30 p.m. **OPEN PUBLIC HEARING**

2:30 p.m. **BREAK**

2:40 p.m. Questions to the Committee/Committee Discussion

4:00 p.m. **ADJOURNMENT**